July 2019: Changes to NCYTO, URCAT2, MYOSPL, RUFIN, LIVFIB, & AJPWO Testing

Special Communication

Changes to NCYTO, URCAT2, MYOSPL, RUFIN, LIVFIB, & AJPWO Testing

Changes to Reference Ranges

Effective August 19, 2019.

Anti-Neut Cyto Ab with Reflex to Titer and MPO/PR3 Ab (NCYTO)

Charting Name Change

Serine Protease 3, IgG will change to Serine Proteinase 3, IgG.

Effective August 19, 2019.

Catecholamines Fractionated by LC-MS/MS, Urine Free (URCAT2)

Reference Ranges: Epinephrine, Urine per 24h

0 – 3 Years:
Not Established

4 – 10 Years:
1 – 14 µg/d

11 – 17 Years:
1 – 18 µg/d

18 – 99 Years:
1 – 14 µg/d

Effective August 19, 2019.

Polymyositis and Dermatomyositis Panel (MYOSPL)

Reference Ranges:

Jo-1 Antibody, IgG

Negative:
29 AU/mL or less

Equivocal:
30 – 40 AU/mL

Positive:
41 AU/mL or greater

PL-7 (threonyl-tRNA synthetase) Antibody:
Negative

PL-12 (alanyl-tRNA synthetase) Antibody:
Negative

EJ (glycyl-tRNA synthetase) Antibody:
Negative

SRP (Signal Recognition Particle) Ab:
Negative

OJ (isoleucyl-tRNA synthetase) Antibody:
Negative

Mi-2 (nuclear helicase protein) Antibody:
Negative

P155/140 Antibody:
Negative

SAE1 (SUMO activating enzyme) Antibody:
Negative

MDA5 (CADM-140) Antibody:
Negative

NXP-2 (Nuclear matrix protein-2) Antibody:
Negative

TIF-1 gamma (155 kDa) Antibody:
Negative

Effective August 19, 2019.

Rufinamide (RUFIN)

Reference Ranges:

Therapeutic Range:
5 – 30 µg/mL

Dose-Related Range (values at dosages of 800 – 7200 mg/day):
3 – 30 µg/mL

Effective September 23, 2019.

Liver Fibrosis, FibroTest-ActiTest (LIVFIB)

Reference Ranges: Fibrosis Interpretation

No fibrosis
FibroTest Score: ≥ 0 and ≤ 0.21
Metavir Score: F0

No fibrosis
FibroTest Score: > 0.21 and ≤ 0.27
Metavir Score: F0 – F1

Minimal fibrosis
FibroTest Score: > 0.27 and ≤ 0.31
Metavir Score: F1

Minimal fibrosis
FibroTest Score: > 0.31 and ≤ 0.48
Metavir Score: F1 – F2

Moderate fibrosis
FibroTest Score: > 0.48 and ≤ 0.58
Metavir Score: F2

Advanced fibrosis
FibroTest Score: > 0.58 and ≤ 0.72
Metavir Score: F3

Advanced fibrosis
FibroTest Score: > 0.72 and ≤ 0.74
Metavir Score: F3 – F4

Severe fibrosis
FibroTest Score: > 0.74 and ≤ 1.00
Metavir Score: F4

Reference Ranges: Necroinflammatory Activity Interpretation

No activity
ActiTest Score: ≥ 0 and ≤ 0.17
Metavir Score: A0

No activity
ActiTest Score: > 0.17 and ≤ 0.29
Metavir Score: A0 – A1

Minimal activity
ActiTest Score: > 0.29 and ≤ 0.36
Metavir Score: A1

Minimal activity
ActiTest Score: > 0.36 and ≤ 0.52
Metavir Score: A1 – A2

Significant activity
ActiTest Score: > 0.52 and ≤ 0.60
Metavir Score: A2

Significant activity
ActiTest Score: > 0.60 and ≤ 0.62
Metavir Score: A2 – A3

Severe activity
ActiTest Score: > 0.62 and ≤ 1.00
Metavir Score: A3

Changes to Test Build

Ashkenazi Jewish Diseases (AJPWO)

Effective August 19, 2019.

Interfaced Clients: These updates may require changes to the Test Build.

Any additional information will be included in a future Technical Update.  If you have any questions about these changes, please contact Client Services for assistance.